In vivo evaluation demonstrated its ability to differentiate tumor lesions expressing PD-L1 protein from those that do not, making [99mTc]Tc-iPD-L1 a potentially useful tool for guiding treatment decisions with anti-PD-L1 immunotherapy in cancer patients. The gene discussed is CD274; the disease is neoplasm.